UMDF Connect

Bench to Bedside – Clinical Trial Updates

Bench to Bedside - Special Edition: Clinical Trial Updates    All answers today are based on personal experience of the participants. As always, please consult your personal physician prior to taking any action.Bnech to Bedside - Special Edition: Clinical Trial...

read more

Ask the Mito Doc – Kygevvi

Ask the Mito Doc - Special Edition: FDA Approval of Kygevvi for TK2d    All answers today are based on personal experience of the participants. As always, please consult your personal physician prior to taking any action.Ask the Mito Doc - Special Edition: FDA...

read more

Ask the Mito Doc – November 2025; Q&A

Ask the Mito Doc - November 2025 Q&A    All answers today are based on personal experience of the participants. As always, please consult your personal physician prior to taking any action.Topic: Genetic Testing in Mitochondrial Disease - What Patients and...

read more

FDA Approves First-Ever TK2d Therapy

11/3/25, 5pm EST -- Earlier today, the U.S. Food and Drug Administration (FDA) approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat the mitochondrial disease thymidine kinase 2 deficiency (TK2d). “It’s hard to put into words what today’s decision means for...

read more